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Starting Antihypertensive Drug Treatment With 
Combination Therapy
Controversies in Hypertension - Con Side of the Argument
Zhen-Yu Zhang , Yu-Ling Yu , Kei Asayama , Tine W. Hansen , Gladys E. Maestre , Jan A. Staessen 
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The 2018 European Society of Cardiology/European Society of Hypertension1 and the 2020 International Society of Hypertension2 guidelines for the manage-
ment of hypertension proposed that initial combination 
therapy with 2 antihypertensive agents in a single-pill 
combination (SPC) is preferred in most patients in need 
of blood pressure (BP) lowering treatment and should 
replace the long-standing concept of starting treatment 
with a single agent, rotating through antihypertensive 
drug classes, and next moving towards combining drug 
classes. By moving SPCs forward as the initial BP-lower-
ing strategy, the European1 and International2 Societies of 
Hypertension Guideline Committees overlooked several 
principles in hypertension management: (1) understand-
ing the pathophysiology of hypertension; (2) prioritizing 
evidence from randomized clinical trials above obser-
vational studies and expert opinion; and (3) giving con-
sideration to the cost-effectiveness of antihypertensive 
drug treatment and the sustainability of health care. This 
article addresses these points. Sources of information 
included (1) guidelines issued by European,1,3,4 Ameri-
can,5–7 International,2,8,9 and British10–12 Expert Commit-
tees, published between 19998 and 2020,2 summarized 
in Table S1 in the Data Supplement; (2) a PubMed search 
ran on May 5, 2020, without limitations with as search 
terms in the abstract or title “hypertension” combined 
with “fixed combination” OR “hypertension” combined 
with “single” and “costs”; (3) the placebo-controlled trials 
of antihypertensive drug treatment, as identified from the 
reference lists of 5 systematic literature reviews,13–17 of 
which 2 were published by the Blood Pressure Lowering 
Trialists’ Collaboration14,16; (4) 3 randomized controlled 
trials of usual versus intensive BP control18–20; and (5) 




In the early 1970s, Laragh’s group coined the terms 
low-renin, normal-renin, and high-renin hypertension by 
relating plasma renin activity to the daily sodium excre-
tion.21 Under normal conditions, plasma renin activity 
increases with sodium restriction but decreases with 
higher BP.21 Although an imperfect generalization, low-
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and its high-renin counterpart by increased peripheral 
resistance,22,23 and are indications to start BP-lowering 
treatment with a diuretic as opposed to an inhibitor of 
the renin-angiotensin system or vasodilator.24 The activ-
ity of the renin system decreases with advancing age22 
and is lower in Blacks compared with Whites.25–27 These 
pathophysiological principles explain why guidelines, 
with the exception of the 2018 European1 and the 2020 
International2 guidelines recommend to start antihyper-
tensive drug treatment with ACE (angiotensin-converting 
enzyme) inhibitors or ARBs below age 55 and with thia-
zide diuretics (TDs) or dihydropyridine CCBs (calcium-
channel blockers) in older patients and in Blacks across 
the adult age range. Isolated systolic hypertension, which 
in its initial course is not associated with increased 
peripheral resistance, but is caused by stiffening of the 
large arteries28 is an indication for TDs29 or CCBs.30,31 
The 2020 International Society of Hypertension guide-
line2 supported the use of thiazide-like diuretics, that is, 
indapamide and chlorthalidone, rather than regular TDs 
(chlorothiazide and hydrochlorothiazide), based on a sys-
tematic review of 19 randomized clinical trials involving 
112 113 patients.32 The observed benefits were mainly 
confined to thiazide-like diuretics rather than TDs with 
reductions in the risk of cardiac events (odds ratio, 0.78; 
P<0.001), heart failure (odds ratio, 0.57; P<0.001), and 
stroke (odds ratio, 0.82; P=0.016).32
ACE inhibitors not only inhibit the generation of active 
angiotensin II, but also the inactivation of the vasodila-
tor bradykinin, explaining their higher potency compared 
with ARBs and direct renin inhibitors and the recommen-
dation to prescribe ARBs only in ACE inhibitor-intolerant 
patients.33,34 The involvement of sympathetic drive and 
the renin-angiotensin system in the cardiovascular and 
renal complications of hypertension and its comorbidities 
clarifies why guidelines1–12 unanimously recommend the 
use ACE inhibitors and ARBs in patients with diabetes 
or chronic kidney disease, and βBs (beta-blockers),35,36 
ACE inhibitors, and ARBs in secondary prevention.
CONTROL RATES ON MONOTHERAPY 
VERSUS COMBINATION THERAPY
With as objective to estimate the proportion of patients 
with hypertension who can be controlled on monotherapy, 
we reviewed the placebo-controlled randomized clinical 
trials listed in systematic reviews of BP-lowering thera-
pies13–17 as well as the trials of intensive versus usual BP 
control.18–20 We extracted control rates on monotherapy 
from the trial reports.
Placebo-Controlled Trials
Table 1 lists the placebo-controlled trials from which the 
proportion of patients remaining on monotherapy could 
be extracted. These trials were published from 198537 
until 2008.38 The first Medical Research Council Trial 
(age range, 35–64 years)37 and the Perindopril Protec-
tion Against Recurrent Stroke Study (age range, not 
reported)39 enrolled adults, but all other recruited older 
patients,30,31,38,40–43 including exclusively38 or a substantial 
proportion of octogenarians.41,42 Considering the patients 
randomized to active treatment, at 2 years, from 25.8%38 
to 90.0%41,42 remained on a single drug and at 4 years 
from 48.0%40 to 87.0%.41,42 In the Hypertension in the 
Very Elderly Trial38 and in the Systolic Hypertension in 
Europe Trial,30 the study coordinating office emailed or 
faxed recommendations for intensification of treatment 
to the local investigators, whenever at a visit a patient 
was not at goal BP, resulting in a substantially smaller 
proportion of patients remaining on monotherapy in 
the placebo compared with the active treatment group 
(Table 1). In the first Medical Research Council Trial,37 
at 4 years of follow-up, 70.0% of patients had attained 
the target BP, defined as a diastolic BP of <90 mm Hg. 
Thus, a substantial proportion of patients remained on 
monotherapy or reached goal BP on a single drug in the 
placebo-controlled trials listed in Table 1.
Intensive Versus Usual BP Control
Of the 3 trials18–20 comparing intensive with usual BP 
control, 219,20 reported on treatment status by randomiza-
tion group. In the ACCORD Trial (Action to Control Car-
diovascular Risk in Diabetes)19 and in SPRINT (Systolic 
Blood Pressure Intervention Trial),20 patients with a sys-
tolic BP of 130 mm Hg or higher and an increased car-
diovascular risk were randomly assigned to a systolic BP 
target of <120 mm Hg (intensive treatment) or a systolic 
target of <140 mm Hg (usual treatment). In the type-2 
diabetic patients randomized to intensive (N=2174) 
and usual (N=2208) BP control in ACCORD,19 after 1 
year, the achieved systolic BP averaged 119.3 mm Hg 
on intensive treatment and 133.5 mm Hg in the control 
group; in SPRINT,20 these levels were 121.4 mm Hg 
(N=4683) and 136.2 mm Hg (N=4683), respectively. 
In ACCORD (median follow-up, 4.7 years),19 at 1 year, 
174 (8.0%) and 265 (28.0%) of patients randomized to 
intensive and standard treatment were on monotherapy 
and at the last visit 184 (8.0%) and 553 (24.0%); in 
SPRINT (median follow-up, 3.3 years),20 these numbers 
at last follow-up were 493 (10.5%) and 1455 (31.1%), 
respectively.
EVIDENCE SUPPORTING SPCS
The literature on SPCs focuses on efficiency, adherence 
(also known as compliance),44 persistence, and safety. 
Over time, these notions permeated to several,1–9 but not 
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Randomized Clinical Trials
Our extensive literature review revealed only one ran-
domized clinical trial comparing the efficacy and safety 
of a SPC with its components.45,46 The COACH Study 
(Combination of Olmesartan Medoxomil and Amlodip-
ine Besylate in Controlling High Blood Pressure) was 
a double-blind trial, conducted at 172 clinical sites in 
the United States.45,46 Patients aged 18 years or older 
with a diastolic BP ranging from 95 to 120 mm Hg were 
randomized in equal proportions to combination therapy 
with olmesartan/amlodipine (daily doses, 10/5, 20/5, 
40/5, 10/10, 20/10, or 40/10 mg) or monotherapy with 
olmesartan (10, 20, or 40 mg) or amlodipine (5 or 10 
mg). Of 4234 patients, who entered the 2-week washout 
phase, 1940 (45.8%) were randomized (women, 45.7%; 
mean age, 54.0 years; mean entry BP, 164/102 mm Hg) 
and 1689 (87.1%) completed the 8-week trial. Predict-
ably, each treatment modality, compared with placebo, 
produced dose-dependent decreases in systolic and dia-
stolic BP and at each dose, combination therapy reduced 
BP more and achieved BP control more frequently 
(<140/<90 and <130/<90 mm Hg in diabetic patients) 
Table 1. Patients Remaining on First-Line Drug Treatment in Placebo-Controlled Randomized Clinical Trials
Trial, publi-
cation year Ref Age, y
Blood pressure, mm Hg
Y Drugs N
Follow-up, number of patients (%)
Entry Goal Year 1 Year 2 Year 3 Year ≥4
HYVET, 
2008
38 83.6, ≥80 173.0/90.8
(≥160/<100) 
<150/<80 1.8 PLAC 1912  100 (14.2)   







NA/<90 4.9 PLAC 8654 … (…)† … (…) … (…) … (…)
… (≈39.9) … (≈41.9) … (≈43.9) … (≈45.9)
↓13.5/6.5* BDF 4927 … (≈81.9) … (≈77.4) … (≈74.3) … (≈72.3)
… (≈63.1) … (≈67.1) … (≈68.1) … (≈70.1)
↓9.5/5.5* PROP 4403 … (≈89.9) … (84.9) … (≈82.4) … (≈79.9)









5.8 PLAC 2213    … (…)
… (…)
↓13.6/7.0* HCTZ/AM 1081 … (62.0)
… (…)




39 65.0, NA 144.0/84.0 (NA) ↓4.9/2.8 3.9 PLAC 1280    … (≈87.0)







>160/>85 3.6 PLAC 845  ≈634 (88.0)  ≈150 (80.0)







<160/<90 2.5 PLAC 815  … (…)   
NIF 817 ≈531 (65.0)
Syst-China, 
1998
31 66.4, ≥60 170.5/86.0  
(160–219/<95)
>150/NA 3.0 PLAC 1141 578 (60.4) 348 (42.9) 203 (30.9) 58 (36.0)
↓20/NA NIT 1253 832 (72.3) 584 (62.7) 374 (51.5) 110 (53.7)
Syst-Eur, 
1997
30 70.3, ≥60 173.8/85.5  
(160–219/<95)
>150/NA 2.0 PLAC 2297 693 (41.2) 343 (27.8) 178 (19.2) 95 (13.9)
↓20/NA NIT 2398 1037 
(59.0)
597 (46.5) 385 (39.3) 216 (30.6)
Age: average age at randomization (age eligibility criterion). Blood pressure: the blood pressure data given are the average systolic/diastolic blood pressure at ran-
domization (blood pressure eligibility criteria) and the goal blood pressure (required decrease in blood pressure). In MRC1, nurses doing screening did 2 sets of BP 
measurements on separate occasions, but to ensure their diagnostic categorization, the third entry BP was done by a physician. As a result, it took nearly 9 months for 
the entry BP to reach its lowest approximately stable level. Mean diastolic BP in women randomized to placebo continued to fall for 5 years. As reported in reference 37, 
only a third (N=2285) had no measurements of diastolic BP below 90 mm Hg at any follow-up visit. Follow-up: Data are the number of patients (percentage) remaining 
on first-line monotherapy. AT indicates atenolol (50–100 mg/d); BDF, bendrofluazide (10 mg/d); CAND, candesartan (8–16 mg/d); HTCZ/AM, hydrochlorothiazide/
amiloride (25/2.5 mg/d); HYVET, Hypertension in the Very Elderly Trial; IND, indapamide (1.5 mg/d); MRC1, Medical Research Council Trial in Young Adults; MRC2, 
Medical Research Council Trial in Older Adults; N, number of patients randomized; NA, not applicable; NIF, nifedipine (20–60 mg/d); NIT, nitrendipine (10–40 mg/d); 
PER, perindopril (4 mg/d); PLAC, matching placebo; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; PROP, propranolol (up to 240 mg/d); SCOPE, 
Study on Cognition and Prognosis in the Elderly; STONE, Shanghai Trial of Nifedipine in the Elderly; Syst-China, Systolic Hypertension in China Trial; Syst-Eur, Systolic 
Hypertension in Europe Trial.; and Y, median or average follow-up on randomized treatment.
*The average placebo-corrected decrease in blood pressure on active treatment.
†An ellipsis indicates that the data could not be extracted from the trial report.
§Number of patients (percentage) reaching goal blood pressure
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than the equivalent dose of the single-component drug. 
Limitations of the COACH trial were selection of patients 
(45.8% of those screened were randomized), the short 
washout (2 weeks) and follow-up (8 weeks), the highly 
predictable BP results,47 and the post hoc analysis of 
patients with isolated systolic hypertension.46
The Simplified Treatment Intervention to Control 
Hypertension Study was a cluster-randomized trial, 
involving 45 family practices in Ontario, Canada and 
compared control rates of hypertension as achieved by 
a simplified treatment algorithm (experimental group) or 
following the Canadian Hypertension Program guideline 
(control group).48 The systolic/diastolic target BP was 
<140/<90 mm Hg and <130/<90 mm Hg in diabetic 
patients. The simplified treatment algorithm consisted 
of the following: (1) initial therapy with a low-dose ACE 
inhibitor/TD or ARB/TD SPC; (2) uptitration of the 
combination therapy to the highest dose; (3) addition 
and subsequent uptitration of a CCB; and (4) addition 
of a βB, α-blocker, or spironolactone. The proportion of 
patients achieving target BP at 6 months was higher in 
the experimental (N=802) than the control (N=1246) 
group (64.7% versus 52.7%; P=0.026). At 6 months, 
82.8% of patients in the experimental group were on 
SPCs and 16.4% in the control group. However, no infor-
mation on BP control beyond 6 months was provided.48
A third randomized double-blind study evaluated the 
efficacy and safety of triple therapy with amlodipine/valsar-
tan/hydrochlorothiazide for moderate or severe hyperten-
sion (systolic/diastolic BP, 145/100 mm Hg or higher).49 
After a 1-week single-blind placebo run-in, patients were 
randomly assigned to valsartan/amlodipine/hydrochloro-
thiazide 320/10/25 mg, valsartan/hydrochlorothiazide 
320/25 mg, valsartan/amlodipine 320/10 mg, or amlo-
dipine/hydrochlorothiazide 10/25 mg with uptitration of 
these once daily SPCs from week 1 to week 3. Of the 
4285 patients screened, 2271 (53.0%) were randomized 
(women, 44.7%; mean age, 53.2 years; mean entry BP, 
169.9/106.5 mm Hg) and 2060 (90.7%) completed the 
8-week trial. Triple therapy was significantly superior to all 
of the dual therapies in reducing BP (P<0.0001).49 Results 
were similar across sex, age, and ethnicity strata. The limi-
tations of this study were like those of the COACH trial.45,46
In the double-blind PATHWAY-1 study (Prevention 
and Treatment of Hypertension With Algorithm-Based 
Therapy Trial),24 of 796 screened patients, 605 (76.0%) 
were randomized and 432 (71.4%) completed the 
1-year follow-up period. Eligible patients were untreated, 
aged 18 to 79 years, and had a self-measured home sys-
tolic/diastolic BP of ≥150/≥95 mm Hg. They were ran-
domized to initial monotherapy with losartan 50 to 100 
mg/d (N=151) or hydrochlorothiazide 12.5 to 25 mg/d 
(N=150), crossing over at 8 weeks (switching to the 
alternative monotherapy), or initial combination treatment 
with losartan 50 to 100 mg/d plus hydrochlorothiazide 
12.5 to 25 mg/d (N=304). In phase 2 (weeks 17–32), 
all patients received losartan 100 mg and hydrochlo-
rothiazide 12.5 to 25 mg. In phase 3 (weeks 33–52), 
amlodipine with or without doxazosin could be added to 
achieve target BP. The primary end point was the change 
in the systolic home BP (target systolic/diastolic home 
BP >140/>90 mm Hg). The original protocol prespeci-
fied the time of the primary end point at the end of phase 
2, namely, 32 weeks after randomization, at which time all 
patients were receiving the same therapy. The statistical 
analysis plan, published before the data lock and unblind-
ing, introduced 2 hierarchical co-primary end points.50 
The first was the reduction in the systolic home BP aver-
aged over phases 1 and 2, testing for the superiority of 
initial combination therapy over monotherapy. The co-
primary end point, to be tested only if the first hypothesis 
was confirmed, was the reduction in systolic home BP at 
week 32, a time point, when all participants were receiv-
ing the same treatment. Comparing initial monotherapy 
with initial combination therapy (Figure 1), the systolic/
diastolic reductions in the home BP were 13.3/6.5 ver-
sus 21.9/12.1 mm Hg (end of phase 1), 20.1/10.7 ver-
sus 19.5/10.6 mm Hg at week 24 (midpoint of phase 
2), 23.6/12.7 versus 22.0/11.9 mm Hg at week 32 (end 
of phase 2), and 24.5/13.9 versus 23.6/13.4 mm Hg at 
week 52 (end of study). By the end of phase 3, over 
75% of participants in the initial monotherapy and com-
bination therapy groups had attained the target home BP 
with no difference between groups at the end of either 
phase 2 or 3.24 Based on the redefinition of the primary 
end points,50 the PATHWAY-1 researchers reported the 
average BP results combining phases 2 and 3 and all 
Figure 1. Systolic home blood pressure (BP) by 
randomization group and follow-up duration.
 Data points are means. Vertical bars indicate 95% CI. Patients 
were randomized to initial monotherapy with losartan (LOS) 50–100 
mg (N=151) or hydrochlorothiazide (HCTZ) 12.5–25 mg (N=150), 
crossing over at 8 weeks (switching to the alternative monotherapy), 
or initial combination treatment with losartan 50–100 mg plus 
hydrochlorothiazide 12.5–25 mg (N=304). In phase 2 (weeks 17–
32), all patients received losartan 100 mg and hydrochlorothiazide 
12.5 to 25 mg. In phase 3 (weeks 33–52), amlodipine with or 
without doxazosin could be added to achieve target BP. SBP 
indicates systolic BP. Reproduced from MacDonald et al24 with 
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study periods.24 They concluded that initial combination 
therapy achieved target BP in twice as many participants 
as initial monotherapy,24 whereas in fact starting from 
week 24 (Figure 1), home BP was similar irrespective 
of whether antihypertensive treatment was started with 
SPC or free SD combination therapy. In the context of 
the current debate, a relevant finding of the PATHWAY-1 
trial was that the BP reductions induced by losartan and 
hydrochlorothiazide were greatest in the top and bottom 
plasma renin activity tertiles, respectively,24 an argument 
supporting an insightful rather than a simplistic initiation 
of antihypertensive drug therapy.
Observational Studies
A common denominator of all observational studies was 
that they had a retrospective design. A meta-analysis 
published in 201151 summarized 12 studies published 
from 200052 until 2010.53 It compared health care costs, 
adherence, and persistence between groups of patients 
taking antihypertensive agents as SPCs versus free-
equivalent SDs. The mean difference in the annual all-
cause and hypertension-related health care costs was 
$1357 (CI, $778–$1935) lower in favor of SPCs than 
free SD combinations. Adherence, measured as the mean 
difference in medication possession ratio, was 8% higher 
in patients naive to prior antihypertensive drugs and 14% 
higher in non-naive SPC patients compared with their 
counterparts on free SD combinations. Persistence in 
the SPC groups was twice as likely as in the free SD 
combination groups (pooled risk ratio, 2.1 [CI, 1.1–4.1]). 
The authors hypothesized that improved adherence and 
persistence likely contributed to the lower health care 
costs in the SPCs groups via improved clinical outcomes. 
Of the 12 studies included in the meta-analysis,52–63 2 did 
not include a conflict of interest statement,54,56 10 were 
directly funded by the pharmaceutical industry,52,53,55,57–63 
and 752,56–59,61,63 had one or more co-authors employed by 
drug companies having a commercial interest in SPCs.
The early literature was almost unanimous in stating 
that SPCs, in comparison with SDs or free combinations 
of SDs, were more efficacious in lowering BP, increas-
ing adherence and persistence, and lowering health care 
costs. In view of this exceptional consistency, we searched 
PubMed for publications with discordant results. We 
identified 10 studies,51,64–72 published between 201064 
until 2020,73 of which the principal outcome measures, 
data sources consulted, the methods applied, and prin-
cipal limitations are summarized in Table S2. Of the 10 
studies,51,64–72 751,64–67,69,70 were directly supported by 
SPCs producers, 551,64–67 involved a subcontractor to 
these manufacturers, and 551,64,65,67,69 were co-authored 
by one or more industry employees. The study by Hong 
et al68 stands out, because it was a publication not sup-
ported by industry, in which none of the authors reported 
a conflict of interest. In this article, free SD combinations 
had average monthly drug costs similar to the respec-
tive SPCs, when SPCs were not generically available.68 
However, free SD combinations were more expensive 
compared with generic SPCs.68
A study published in 2020 without industry support,72 
applied the 2014 to 2015 Medical Expenditure Panel 
Survey data, to assess the uses and expenses of antihy-
pertensive drugs among American men and nonpregnant 
women, aged 18 or older, who had a diagnosis of hyper-
tension. Multiple medications users were patients who 
used 2 or more antihypertensive medications each year, 
including SPCs or multiple free SD combinations, or who 
switched BP-lowering agents within or between classes. 
Among 10 971 hypertensive adults, 4759 (44.1%) were 
SD users and 6212 (55.9%) were multiple medication 
users. The average annual total cost for antihypertensive 
medications was $336 per person: $199 for SD users 
and $436 for multiple medication users. The average 
annual costs for each medication class were estimated 
at $438 for ARBs and $49 for TDs. Thus, users of mul-
tiple medications, including SPCs, incurred more than 
twice the expense than single medication users.72 When 
comparing classes of medications, the costs for ARBs 
were highest, whereas those for TDs were lowest (Fig-
ure 2), a trend still visible in the 2020 retail prizes of anti-
hypertensive drugs on the Belgian market (Table S3).72
Several studies addressed the health-economic 
aspects of the use of SPCs versus SDs or free combina-
tions of SDs,65–67,70,73 or triple versus dual SPCs.69 Data 
from the MarketScan Database 2006 to 2008 in the 
United States showed that SPC patients (N=382 476) 
fared better over a 6-month period than their counter-
parts on free SD combinations (N=197 375).73 The 
analyses were adjusted for the baseline characteristics 
of the selected patients, a reason why this article73 was 
excluded from the 2011 meta-analysis.51 SPC patients 
had higher medication possession rates (+11.6%), fewer 
all-cause hospitalizations (−23.0%), and emergency 
room visits (−13.0%). SPC patients showed greater 
reductions in post-therapy initiation in all-cause medical 
costs ($208 [CI, −$302 to −$114]), but larger increases 
in hypertension-related prescription costs (+$53 [CI, 
+$51 to +$55]).73 Similarly, in a study conducted in UK 
general-practice, hospitalization costs validated up to 
2011 were lower in SPC patients compared with free 
SD users (N=9929 versus 18 665; £62 versus £112; 
P<0.001), whereas drug costs were higher (£126 versus 
£78; P<0.001), resulting in similar mean annual man-
agement costs in the 2 groups (£192 versus £192).66
All observational reviewed above (Table S2) had a 
retrospective design and were, therefore, vulnerable 
to overt and hidden sources of bias, for which analy-
ses did not account. Particularly, most studies had no 
information on the severity of hypertension at the time 
of initiation or adjustment of BP-lowering treatment, 
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drugs, or on the patients’ health insurance status as 
determinant of the out-of-pocket costs and adherence 
(Table S2). Data on health behaviors, patients’ lifestyle, 
and use of over-the-counter drugs were unavailable. 
In several analyses, there was a remarkable imbalance 
between SPC and free SD combination users,65–67,73 
indicating selection bias in the patients being pre-
scribed SPCs versus free SD combinations or in data 
extraction from the claims databases by researchers. 
Medication possession rate, although an objective 
measure, but only in settings with a closed pharmacy 
system,44 is an ambiguous concept. Although there is 
moderate association between claims for filled pre-
scriptions and measured drug levels44 or prevention 
of adverse health outcomes,74 claims databases do not 
ensure that the medication was taken as prescribed. 
Moreover, information from claims databases disfavors 
free SD drug combinations, because in their publica-
tions investigators selected the SD with the worse 
adherence,73 or when 2 or more SDs were prescribed, 
probabilities of nonadherence were multiplicative, not 
additive. Furthermore, the claims data used for the 
health-economic analyses were collected for payment 
purposes rather than for research. A diagnostic code 
on a medical claim is no proof for the presence of dis-
ease, because diagnoses might be incorrectly coded 
or included as a rule-out criterion rather than as an 
actual disease. All reviewed health-economic studies 
only accounted for direct health care costs, disregard-
ing patient values,75 and out-of-pocket costs.71 A fol-
low-up duration ranging from 6 months64 to 5 years66 
is not representative of the life course of hyperten-
sion. No study measured adverse health outcomes in 
a prospective manner (Table S2). Transitions between 
health states applied in Markov modeling were not 
directly measured, but extrapolated,69,70 introducing 
arbitrariness in selecting data sources best fitting the 
hypothesis to be proven.
Narrative Reviews
Of 7 reviews on the use of SPCs,76–82 published from 
200976 until 2019,82 6 were written with direct finan-
cial support from SPC manufacturers,77–82 3 included 
co-authors employed by these manufacturers,77,79,82 2 
involved a for-profit company running the literature 
search77 or providing assistance in writing the text,78 and 
1 article’s co-author received research support from a 
company marketing SPCs.76
TAKE HOME MESSAGES
Table 2 lists the major limitations of the recommended 
policy to initiate antihypertensive treatment using SPCs 
in most patients.1,2
Weaknesses of Current Guidelines
Lengthy guidelines comprehensible only by hypertension 
specialists, lead to therapeutic inertia in primary care and 
fall short of their very reason of existence. The 98-page 
2018 European recommendations1 go as far as stating 
that initial combination therapy is invariably more effec-
tive in lowering BP than monotherapy and is, therefore, 
indicated in most patients. The reference cited to sub-
stantiate this claim was a meta-analysis, not of SPCs 
versus SD free combinations, but comparing treatment 
strategies consisting of increasing the dose of the first-
line antihypertensive agent or adding a second drug 
class.47 Two of its authors held patents for a combina-
tion pill (polypill) for the prevention of cardiovascular dis-
ease.47 To permeate clinical practice, recommendations 
must excel in simplicity, allowing summarizing key issues 
in a simple mnemonic rule, such as the AB/CD algorithm 
in the 2006 British guideline (Figure 3).10 Admittedly, the 
position of βBs as first-line treatment remains a matter 
of debate, albeit not in the last author’s interpretation of 
the literature.36,83 One might argue that SPCs combining 
Figure 2. Estimated average 
annual per capita expenses of each 
medication class (95% CI), expressed 
in US dollars based on the 2014–2015 
Medical Expenditure Panel Survey 
Notes.
 ACEI indicates angiotensin-converting 
enzyme inhibitor; ARB, angiotensin 
receptor blocker; CCB, calcium-channel 
blocker; and TD, thiazide diuretics. 
Reproduced from Park et al72 with 
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a βB and an ACE inhibitor, as for instance marketed in 
Belgium (www.bcfi.be) might allow initiating treatment in 
high-renin hypertensive patients in line with pathophysi-
ologic insights, but in line with the older literature84 no 
guideline1–12 supports this combination for BP lowering. 
Nevertheless, guidelines do support such combination in 
secondary prevention.
The pharmaceutical industry is an important motor in 
creating therapeutic innovation. To remain profitable, there 
is nothing wrong in SPC manufacturers highlighting the 
potential benefits of their products. However, a problem 
arises when retrospective observational studies52–72 (Table 
S2) or systematic51 or narrative76–82 reviews of such stud-
ies become the source of information in evidence-based 
recommendations. Guidelines should be incremental over 
time, meaning that evidence published between succes-
sive versions should lead to removing or adjusting previ-
ous recommendation or introducing new ones. The British 
guidelines10–12 are exemplary in this respect, giving great 
weight to new evidence as justification for any change 
in treatment advice (Table S1). The 2019 National Insti-
tute for Health and Care Excellence recommendation11 
stated that there was some limited evidence from a single 
study85 that initial dual therapy, compared with placebo, 
might reduce cardiovascular complications in people with 
hypertension and type-2 diabetes, but the Committee 
Members were disappointed that more comprehensive 
data were unavailable.11 The Committee discussed the 
benefits of optimizing treatment for hypertension early 
and agreed that this could substantially improve quality 
of life. However, they found that there was not enough 
evidence to determine confidently the benefits or harms 
of starting antihypertensive treatment with dual therapy.11
The 2018 European guideline1 went on proposing that 
the combination of medications targeting multiple mecha-
nisms, such as blocking the renin-angiotensin system and 
inducing vasodilatation and diuresis, reduces the heteroge-
neity of the BP responses to initial treatment and provides 
a steeper dose response than is observed with escalating 
doses of monotherapy.1 Whereas this might be true during 
first 6 months after starting BP-lowering treatment,50,86 this 
certainly does not apply to the long-term life course treat-
ment of hypertension (Figure 1). A post hoc analysis of the 
Table 2.  Take Home Messages
Issue Summary of the literature
RCTs Lack of RCTs comparing the long-term efficiency, adverse 
effects, and cost-effectiveness of initiating antihyperten-
sive drug treatment with SPCs as compared with free 
combinations of SDs. The scarce RCT evidence currently 
available shows that 3 months after initiation of treatment 
BP is not better controlled by SPCs than free combina-
tions of SDs. The literature does not support the notion 
that early BP control leads to long-term benefit in the 
prevention of cardiovascular end points.
Observational 
studies
Short-term observational studies, most with retrospec-
tive design and short duration (<6 months), are the main 
source of information supporting European and Interna-
tional recommendations to start antihypertensive treat-
ment with SPCs. In retrospective observational studies 
of SPCs, adverse effects cannot be associated with a 
drug class, but are vaguer and more difficult to pick up, 
such as fatigue or hypotension, are under-reported.
Sponsors Manufacturers of SPCs sponsored almost all studies, 
explaining bias in choosing data sources informing 
health-economic analyses, definitions of nonadher-
ence to SDs, and the complete absence of dissonant 
results in the literature.
Health care costs Use of SPCs increase drug costs, mainly due to the 
high retail price of sartans; SPCs do not reduce over-
all health care costs.
Components of 
SPCs
The diuretic in SPCs is overwhelmingly the short-act-
ing hydrochlorothiazide, whereas preference should 
be given to the long-acting chlorthalidone. SPCs com-
bining a βB and an ACEI are not guideline-endorsed.
Ease of use SPCs lack flexibility in combining and dosing individual 
drug classes and in spreading dosing of drugs over 
the day. Patients with chronic disease value minimizing 
side-effects and long-term toxicities over frequency of 
dosing and other administration characteristics.
βB indicates β-blockers; ACEI, angiotensin-converting enzyme inhibitors; BP, 
blood pressure; RCT, randomized clinical trial; SDs, single drugs; and SPCs, sin-
gle-pill combinations.
Figure 3. Recommendation for 
combining blood pressure-lowering 
drugs.
 First-line drugs with different modes of 
action should be combined according to 
the AB/CD rule. Reproduced from British 
Cardiac Society, British Hypertension 
Society, Diabetes UK, HEART UK, 
Primary Care Cardiovascular Society, The 
Stroke Association10 with permission. 
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Valsartan Antihypertensive Long-Term Use Evaluation Trial 
did not confirm the widely promoted notion in SPC publi-
cations that earlier short-term differences in BP lowering 
over the long run would reduce cardiovascular end points.87 
Furthermore, the European1 and International2 Societies of 
Hypertension instructions ignored that the association of 
multiple drugs in a single pharmaceutical formulation may 
have effects on the pharmacokinetic and pharmacodynamic 
properties of each and every individual component and may 
lead to undesired interactions between components.88,89 
The trials45,46,48–50 and observational studies51–72 reviewed 
in this debate article were generally not powered or had 
a duration not long enough to highlight serious adverse 
effects. As demonstrated by an observational study of 
patients aged 50 years or more and reflecting a real-world 
setting, use of SPCs was associated with a greater risk of 
hypotension than titrated SD free combinations.90 Moreover, 
abstraction made of commonly attributable adverse effects, 
for example, leg edema or cough respectively on treatment 
with CCBs or ACE inhibitors, many drug-induced com-
plaints are vaguer and more difficult to be picked up, such 
as for instance fatigue or dizziness and in theory require 
rechallenge with the SD components of an SPC to identify 
the culprit drug. Fewer pills to be taken daily is a central 
concept in the promotion of SPCs,91 but a literature review 
with as search terms “preference” AND “patient” AND “pills” 
or “SPC”, ran on October 20, 2020, with no limitations, did 
not yield any article among the 46 hits that directly trans-
lated patient convenience into preference for SPCs in pri-
mary or secondary cardiovascular prevention. As a corollary, 
treatment-experienced persons living with HIV valued mini-
mizing side-effects and long-term toxicities over dosing and 
administration characteristics.92 Preferences varied widely,92 
highlighting the need to elicit individual patient preferences, 
when decisions about dosing schemes of medications are 
made, certainly in the light of the potential adverse events 
of SPCs as mentioned before. Finally, the advice to initiate 
antihypertensive drug therapy with SPCs also goes against 
pathophysiological principles supporting the use of TDs in 
low-renin hypertension, Blacks and older patients and the 
use vasodilators (ACE inhibitors, ARBs, or CCBs) in high-
renin patients or younger individuals (Figure 3).
In an era of epidemiological transition,93 payers, doc-
tors, and patients should join forces to keep health care 
sustainable in aging populations. In the placebo-controlled 
outcome trials (Table 1),30,31,37–43 a substantial proportion 
of hypertensive patients could be controlled on a single 
drug. Arguably, the entry and target BPs in these tri-
als were higher than those currently proposed. However, 
mutatis mutandis, lower BP levels, at which antihyperten-
sive drug treatment should be initiated,7 would increase the 
control rates on monotherapy. BP lowering to <140/90 
mm Hg was achieved by monotherapy in about one-third of 
patients randomized to standard treatment in ACCORD19 
and SPRINT.20 In needy patients, out-of-pocket costs are 
a major hurdle in long-term adherence.71 In a Canadian 
cluster-randomized trial involving 76 primary care prac-
tices,71 3592 patients with uncomplicated hypertension 
were followed up for 5 years. Physicians were random-
ized to an out-of-pocket expenditure software module 
that provided alerts for out-of-reimbursement costs and 
recommended TDs as first-line therapy and control. In the 
intervention group, there was a significant increase in the 
prescription of TDs in newly treated patients (26.6% versus 
19.8%). For patients already treated, older patients were 
less likely to be switched to a TD. Translating these find-
ings to the Belgian context (Table S3), starting a patient on 
monotherapy with low-dose treatment with chlorthalidone, 
bisoprolol, amlodipine, perindopril, valsartan, or olmesartan 
entails an annual cost of €19, €38, €44, €72, €87, and 
€107, respectively, if the drug with the lowest retail prize 
would be prescribed; the corresponding annual expense 
for the lowest-cost SPC with valsartan/hydrochlorothiazide, 
olmesartan/hydrochlorothiazide, valsartan/amlodipine, and 
olmesartan/amlodipine amounts to €85, €107, €128, and 
€141. Giving that one-third of the patients started on anti-
hypertensive therapy can be controlled by a SD, the poten-
tial savings for the Belgian health insurance are huge, if 
patients would no longer be started on dual SPCs.
Rational Use of SPCs
We proposed that starting antihypertensive therapy in 
treatment-naive hypertensive patients might be based on 
a few simple principles. First, use antihypertensive drugs 
with different modes of action in line with the AB/CD 
algorithm (Figure 3). Second, use antihypertensive agents 
with a long duration of action based on their molecular 
structure, so-called forgiving drugs, rather than extended-
release dosage formulations.94,95 Third, titrate each drug to 
the highest dose that does not produce adverse effects. 
Fourth, include a thiazide in the drug combination. Finally, 
once the right combination has been found by rotating 
through and combining drug classes as well as the tim-
ing of dosing, stimulate adherence by reducing the pill 
load by prescribing SPCs including 2 or 3 antihyperten-
sive agents in adjustable doses. Initiating antihyperten-
sive drug treatment with SDs overcomes the inflexibility 
of SPCs in titrating the doses of the SD components and 
the timing of their administration, for instance to prevent 
nocturnal diuresis or hypotension. In line with the above 
proposal, in Japan, only one triple-drug SPC is being 
marketed (telmisartan/amlodipine/hydrochlorothiazide 
80/5/12.5 mg). It can only be prescribed after 8 weeks 
of successful treatment with its components given as dual 
SPCs plus one SD or as free 3-drug SD combinations
None of the trials of SPCs had a cardiovascular end point. 
In line with the 2019 National Institute for Health and Care 
Excellence guideline,11 an important research issue is to 
mount outcome-driven randomized clinical trials to delineate 
particular subgroups of hypertensive patients who might 
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with hydrochlorothiazide, chlorthalidone is 1.5 to 2.0 × more 
potent, has a substantially longer duration of action (plasma 
half-life, 8 versus >24 hours), and is not metabolized but 
excreted unchanged in urine, thereby preventing drug-drug 
interactions.32,95 Unfortunately, the diuretic in SPCs currently 
marketed is overwhelmingly hydrochlorothiazide, an issue 
to be addressed by manufacturers (Table 2). Finally, payers 
should better inform physicians and patients on the costs of 
antihypertensive drugs to reduce health care costs, decrease 
out-of-pocket costs as a factor limiting adherence,71 and to 
support the sustainability of health care by lower drug costs 
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Response to Starting Antihypertensive Drug Treatment With Combination Therapy: 
Controversies in Hypertension - Con Side of the Argument
Alexandre Persu , Marilucy Lopez-Sublet, Engi Abd El-Hady Algharably, Reinhold Kreutz 
Jan Staessen is an internationally recognized expert known for his independent and integer positions. He and his 
coauthors have produced a highly informative, original document against the extensive use of first-line single-pill 
combinations.
Still, we feel that it does not detract from our plea in favor of the use of combination therapy as first-line 
treatment in most patients with hypertension. Although studies supporting the benefit of this compared to other 
strategies have limitations, this is also the case for other treatment strategies used in daily practice. For example, 
the arguments in favor of the National Institute for Health and Care Excellence algorithm supported by Staes-
sen and colleagues rest more on clinical expertise and general principles of pharmacology than on rigorously 
designed randomized controlled trials.
The recommendation to use dual antihypertensive therapy in most patients with hypertension is more a public 
health than a trialist’s perspective.
As indicated by Prof. Staessen, two-thirds of patients with hypertension eventually need ≥2 antihypertensive 
drugs to achieve blood pressure control.
We simply think that using single-pill combinations as first-line therapy in those patients is the most effective way 
to overcome poor drug adherence and inertia, currently the main barriers to improve blood pressure control worldwide.
Admittedly, this recommendation may benefit the pharma industry. However, it is the responsibility of public 
health authorities to negotiate properly the price of single-pill combinations while supporting less expensive, 
generic alternatives.
Finally, the gap between Prof. Staessen’s and our conception is less wide than it may appear.
While he focuses on cases in which monotherapy is the preferred approach—basically the same as us, patients 
with mild hypertension, particularly older patients with isolated systolic hypertension—we emphasize the big picture in 
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